Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 16/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18009241 | 1.00 | HCAR2 (0.38) | HCAR2KEAP1NFE2L2IRAK4IRAK1 | |
| SCHEMBL18009250 | 1.00 | HCAR2 (0.38) | HCAR2KEAP1NFE2L2IRAK4IRAK1 | |
| SCHEMBL18009354 | 0.92 | MGLL (0.39) | IRAK4IRAK1MGLL | |
| SCHEMBL18199448 | 0.88 | IRAK4 (0.35) | IRAK4IRAK1MGLL | |
| SCHEMBL18014862 | 0.88 | HCAR2 (0.42) | HCAR2IRAK4MGLL | |
| SCHEMBL18014839 | 0.87 | HCAR2 (0.40) | HCAR2IRAK4IRAK1MGLL | |
| SCHEMBL18014831 | 0.85 | IRAK4 (0.38) | IRAK4IRAK1MGLL | |
| SCHEMBL18014829 | 0.85 | HCAR2 (0.39) | HCAR2IRAK4MGLL | |
| SCHEMBL18014901 | 0.84 | MGLL (0.35) | IRAK4IRAK1MGLL | |
| SCHEMBL18014884 | 0.84 | HCAR2 (0.37) | HCAR2KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630934-B2 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630934-B2 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-04-25 | — | — | US | disclosed |
| WO-2016127186-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2016-08-11 | — | — | WO | disclosed |
| US-20160229819-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229819-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229819-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | HCAR2 290/4885KEAP1 468/4885NFE2L2 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.